Fgcl-3019-087- A Phase 3, Randomized, Double-Blind Study Of Pamrevlumab Or Placebo In Combination With Gemcitabine Plus Nab-Paclitaxel (G/Np) As Neoadjuvant Treatment In Patients With Locally Advanced, Unresectable Pancreatic Cance
Posted Date: Dec 17, 2020
- Investigator: Davendra Sohal
- Specialties: Cancer, Oncology, Pancreatic Cancer
- Type of Study: Drug
The main goal of this study is to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combination with gemcitabine plus nab-paclitaxel (G/NP) in the treatment of locally advanced, unresectable pancreatic cancer. Each subject may receive up to six cycles of treatment (each treatment cycle is 28 days).
Criteria:
To Be Eligible: Must Have Diagnosis Of Pancreatic Ductal Adenocarcinoma, Ecog 0-1, Measurable Disease, No Prior Chemo Or Radiation For Study Cancer, No Previous Malignancy Within 3 Years, No Uncontrolled Intercurrent Illness, No Major Surgery Within 4 Weeks
Keywords:
Pancreatic Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com